- Home
- HTCR vs BTAI Comparison
HTCR vs BTAI Comparison
Compare HTCR & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTCR
- BTAI
- Stock Information
- Founded
- HTCR 2009
- BTAI 2017
- Country
- HTCR Japan
- BTAI United States
- Employees
- HTCR N/A
- BTAI N/A
- Industry
- HTCR EDP Services
- BTAI Biotechnology: Pharmaceutical Preparations
- Sector
- HTCR Technology
- BTAI Health Care
- Exchange
- HTCR Nasdaq
- BTAI Nasdaq
- Market Cap
- HTCR 12.8M
- BTAI 10.7M
- IPO Year
- HTCR 2022
- BTAI 2018
- Fundamental
- Price
- HTCR $0.66
- BTAI $1.18
- Analyst Decision
- HTCR
- BTAI Buy
- Analyst Count
- HTCR 0
- BTAI 5
- Target Price
- HTCR N/A
- BTAI $42.60
- AVG Volume (30 Days)
- HTCR 2.5M
- BTAI 403.0K
- Earning Date
- HTCR 05-15-2025
- BTAI 05-12-2025
- Dividend Yield
- HTCR 3.03%
- BTAI N/A
- EPS Growth
- HTCR N/A
- BTAI N/A
- EPS
- HTCR N/A
- BTAI N/A
- Revenue
- HTCR $28,947,523.00
- BTAI $1,852,000.00
- Revenue This Year
- HTCR N/A
- BTAI $27.23
- Revenue Next Year
- HTCR N/A
- BTAI $217.72
- P/E Ratio
- HTCR N/A
- BTAI N/A
- Revenue Growth
- HTCR 59.42
- BTAI 5.47
- 52 Week Low
- HTCR $0.51
- BTAI $1.17
- 52 Week High
- HTCR $3.38
- BTAI $30.88
- Technical
- Relative Strength Index (RSI)
- HTCR 53.68
- BTAI 27.79
- Support Level
- HTCR $0.51
- BTAI $1.39
- Resistance Level
- HTCR $0.78
- BTAI $1.48
- Average True Range (ATR)
- HTCR 0.06
- BTAI 0.11
- MACD
- HTCR 0.02
- BTAI -0.01
- Stochastic Oscillator
- HTCR 55.99
- BTAI 2.38
About HTCR Heartcore Enterprises Inc.
HeartCore Enterprises Inc is a software development company. The company provides software through two business units. The first business unit includes a customer experience management business. The customer experience management platform includes marketing, sales, service, and content management systems, as well as other tools and integrations that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, DX division, is a digital transformation business that provides customers with robotics process automation, process mining, and task mining to accelerate the digital transformation of enterprises.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.